Overall survival (OS) with afatinib (A) vs chemotherapy (CT) in patients (pts) with NSCLC harboring EGFR mutations (mut): Subgroup analyses by race in LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)

被引：0
|
作者：
Wu, Y. -L. [1 ,2 ]
Sequist, L. V. [3 ,4 ]
Schuler, M. [5 ]
Yamamoto, N. [6 ]
Zhou, C. [7 ]
Hu, C. -P. [8 ]
O'Byrne, K. [9 ,10 ]
Hirsh, V. [11 ]
Mok, T. [12 ]
Zazulina, V. [13 ]
Yang, J. C. -H. [14 ,15 ]
机构：
[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Massachusetts Gen Hosp, Dept Thorac Oncol, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
[5] Univ Hosp Essen, Univ Duisburg Essen, West German Canc Ctr, Essen, Germany
[6] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan
[7] Tongji Univ, Shanghai Pulm Hosp, Shanghai 200092, Peoples R China
[8] Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China
[9] Princess Alexandra Hosp, Translat Res Inst, Brisbane, Qld 4102, Australia
[10] Queensland Univ Technol, Brisbane, Qld 4001, Australia
[11] McGill Univ, Dept Oncol, Montreal, PQ, Canada
[12] Chinese Univ Hong Kong, State Key Lab South China, Hong Kong Canc Inst, Hong Kong, Hong Kong, Peoples R China
[13] Boehringer Ingelheim Ltd UK, Med, Bracknell, Berks, England
[14] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[15] Natl Taiwan Univ, Taipei 10764, Taiwan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
445P
引用
收藏
页码：136 / 136
页数：1
相关论文
共 50 条
  • [21] Central Nervous System or Systemic Progression Analysis for EGFR Mutation-Positive NSCLC Patients Receiving Afatinib in LUX-Lung 3, 6, and 7
    O'Byrne, K.
    Yang, J. C-H
    Wu, Y-L
    Hirsh, V.
    Yamamoto, N.
    Popat, S.
    Tamiya, A.
    Maerten, A.
    Schuler, M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 69 - 69
  • [22] Analysis of overall survival (OS) in two large open-label phase III studies (L-Lung 3 [LL3] and L-Lung 6 [LL6]) comparing afatinib eth chemotherapy (CT) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Deli9/L858R) epidermal gro factor receptor mutations (EGFR mut)
    Sebastian, Martin
    Yang, James Chih-Hsin
    Sequist, Lecia
    Schuler, Martin
    Mok, Tony
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth
    Hirsh, Vera
    Geater, Sarayut
    Zhou, Caicun
    Massey, Dan
    Zazulina, Victoria
    Wu, Yi-Long
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [23] First-line afatinib for advanced EGFRm1 NSCLC: Analysis of long-term responders (LTRs) in the LUX-Lung (LL) 3, 6 and 7 trials
    Schuler, M.
    Paz-Ares, L.
    Sequist, L. V.
    Wu, Y-L.
    Geater, S. L.
    Maerten, A.
    Fan, J.
    Park, K.
    Yang, J. C-H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7
    Yang, J. C-H.
    Wu, Y-L.
    Hirsh, V.
    O'Byrne, K.
    Yamamoto, N.
    Popat, S.
    Tamiya, A.
    Maerten, A.
    Schuler, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S84 - S85
  • [25] Afatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm1) NSCLC: Updated OS data from the phase IIb trial LUX-Lung 7 (LL7)
    Corral, J.
    Park, K.
    Yang, J. C-H.
    Mok, T.
    Tan, E-H.
    O'Byrne, K.
    Hirsh, V.
    Boyer, M.
    Fan, J.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials
    Yang, J. C. -H.
    Sequist, L. V.
    Zhou, C.
    Schuler, M.
    Geater, S. L.
    Mok, T.
    Hu, C. -P.
    Yamamoto, N.
    Feng, J.
    O'Byrne, K.
    Lu, S.
    Hirsh, V.
    Huang, Y.
    Sebastian, M.
    Okamoto, I.
    Dickgreber, N.
    Shah, R.
    Maerten, A.
    Massey, D.
    Wind, S.
    Wu, Y. -L.
    ANNALS OF ONCOLOGY, 2016, 27 (11) : 2103 - 2110
  • [27] Phase III trial of afatinib vs erlotinib in patients (pts) with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes
    Park, K.
    Li, W.
    Zhou, C.
    Felip, E.
    Cobo, M.
    Goss, G. D.
    Soria, J. -C.
    Syrigos, K.
    Kraemer, N.
    Chand, V. K.
    Solca, F.
    Lu, S.
    ANNALS OF ONCOLOGY, 2015, 26 : 135 - 135
  • [28] Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial
    Wu, Yi-Long
    Xu, Chong-Rui
    Hu, Cheng-Ping
    Feng, Jifeng
    Lu, Shun
    Huang, Yunchao
    Li, Wei
    Hou, Mei
    Shi, Jian Hua
    Maerten, Angela
    Fan, Jean
    Peil, Barbara
    Zhou, Caicun
    ONCOTARGETS AND THERAPY, 2018, 11 : 8575 - 8587
  • [29] Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)
    Yi-Long Wu
    Vera Hirsh
    Lecia V. Sequist
    Cheng-Ping Hu
    Jifeng Feng
    Shun Lu
    Yunchao Huang
    Martin Schuler
    Tony Mok
    Nobuyuki Yamamoto
    Kenneth O’Byrne
    Sarayut L. Geater
    Caicun Zhou
    Dan Massey
    Angela Märten
    Juliane Lungershausen
    James Chih-Hsin Yang
    The Patient - Patient-Centered Outcomes Research, 2018, 11 : 131 - 141
  • [30] EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6
    Wu, Yi-Long
    Sequist, Lecia V.
    Hu, Cheng-Ping
    Feng, Jifeng
    Lu, Shun
    Huang, Yunchao
    Li, Wei
    Hou, Mei
    Schuler, Martin
    Mok, Tony
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth
    Hirsh, Vera
    Gibson, Neil
    Massey, Dan
    Kim, Miyoung
    Yang, James Chih-Hsin
    BRITISH JOURNAL OF CANCER, 2017, 116 (02) : 175 - 185
12345